0 100

Cited 0 times in

Entecavir versus tenofovir on the recurrence of hepatitis B-related HCC after liver transplantation: A multicenter observational study

Authors
 Deok-Gie Kim  ;  YoungRok Choi  ;  Jinsoo Rhu  ;  Shin Hwang  ;  Young Kyoung You  ;  Dong-Sik Kim  ;  Yang Won Nah  ;  Bong-Wan Kim  ;  Jai Young Cho  ;  Koo Jeong Kang  ;  Jae Do Yang  ;  Donglak Choi  ;  Dong Jin Joo  ;  Myoung Soo Kim  ;  Je Ho Ryu  ;  Jae Geun Lee  ;  Korean Organ Transplantation Registry Study Group 
Citation
 LIVER TRANSPLANTATION, Vol.29(12) : 1272-1281, 2023-12 
Journal Title
LIVER TRANSPLANTATION
ISSN
 1527-6465 
Issue Date
2023-12
MeSH
Antiviral Agents / therapeutic use ; Carcinoma, Hepatocellular* / epidemiology ; Hepatitis B virus ; Hepatitis B* / complications ; Hepatitis B* / diagnosis ; Hepatitis B* / drug therapy ; Hepatitis B, Chronic* / complications ; Hepatitis B, Chronic* / diagnosis ; Hepatitis B, Chronic* / drug therapy ; Humans ; Liver Neoplasms* / epidemiology ; Liver Transplantation* / adverse effects ; Tenofovir / therapeutic use ; Treatment Outcome
Abstract
Considerable controversy exists regarding the superiority of tenofovir disoproxil fumarate (TDF) over entecavir (ETV) for reducing the risk of HCC. This study aimed to compare outcomes of ETV versus TDF after liver transplantation (LT) in patients with HBV-related HCC. We performed a multicenter observational study using data from the Korean Organ Transplantation Registry. A total of 845 patients who underwent LT for HBV-related HCC were divided into 2 groups according to oral nucleos(t)ide analogue used for HBV prophylaxis post-LT: ETV group (n = 393) and TDF group (n = 452). HCC recurrence and overall death were compared in naïve and propensity score (PS)-weighted populations, and the likelihood of these outcomes according to the use of ETV or TDF were analyzed with various Cox models. At 1, 3, and 5 years, the ETV and TDF groups had similar HCC recurrence-free survival (90.7%, 85.6%, and 84.1% vs. 90.9%, 84.6%, and 84.2%, respectively, p = 0.98) and overall survival (98.4%, 94.7%, and 93.5% vs. 99.3%, 95.8%, and 94.9%, respectively, p = 0.48). The propensity score-weighted population showed similar results. In Cox models involving covariates adjustment, propensity score-weighting, competing risk regression, and time-dependent covariates adjustment, both groups showed a similar risk of HCC recurrence and overall death. In subgroup analyses stratified according to HCC burden (Milan criteria, Up-to-7 criteria, French alpha-fetoprotein risk score), pretransplantation locoregional therapy, and salvage LT, neither ETV nor TDF was superior. In conclusion, ETV and TDF showed mutual noninferiority for HCC outcomes when used for HBV prophylaxis after LT.
Full Text
https://journals.lww.com/lt/fulltext/2023/12000/entecavir_versus_tenofovir_on_the_recurrence_of.7.aspx
DOI
10.1097/lvt.0000000000000227
Appears in Collections:
1. College of Medicine (의과대학) > Dept. of Surgery (외과학교실) > 1. Journal Papers
Yonsei Authors
Kim, Deok Gie(김덕기)
Kim, Myoung Soo(김명수) ORCID logo https://orcid.org/0000-0002-8975-8381
Lee, Jae Geun(이재근) ORCID logo https://orcid.org/0000-0002-6722-0257
Joo, Dong Jin(주동진) ORCID logo https://orcid.org/0000-0001-8405-1531
URI
https://ir.ymlib.yonsei.ac.kr/handle/22282913/196820
사서에게 알리기
  feedback

qrcode

Items in DSpace are protected by copyright, with all rights reserved, unless otherwise indicated.

Browse

Links